Viagra vs Vardenafil (Levitra/Staxyn) in Special Populations: Head-to-Head

How Sildenafil and Vardenafil Work

Both drugs inhibit phosphodiesterase type 5 (PDE5), the enzyme that breaks down cyclic GMP in penile smooth muscle. Blocking PDE5 keeps blood vessels dilated during sexual stimulation, allowing an erection. Vardenafil binds PDE5 with roughly 10-fold greater potency than sildenafil in vitro, though in-vitro potency does not always translate directly to clinical superiority.

Mechanism Differences That Matter Clinically

Vardenafil has a higher selectivity ratio for PDE5 over PDE6, the enzyme responsible for visual disturbances. This means men on sildenafil report transient blue-tint vision or photosensitivity more often than men on vardenafil. Goldstein et al. (NEJM, 1998) documented a 3% rate of abnormal vision in the landmark sildenafil RCT, an adverse event driven by off-target PDE6 inhibition.

Sildenafil also inhibits PDE11 to a small degree. PDE11 is expressed in cardiac and skeletal muscle, and its inhibition may contribute to mild myalgia. Vardenafil's selectivity profile is narrower at clinically relevant doses.

Pharmacokinetic Comparison

| Parameter | Sildenafil (Viagra) | Vardenafil (Levitra) | Vardenafil ODT (Staxyn) | |---|---|---|---| | Tmax | 30 to 120 min | 30 to 120 min | ~60 min | | Half-life | ~4 hours | ~4 to 5 hours | ~4 to 5 hours | | Bioavailability | ~41% | ~15% | Slightly higher than tablet | | High-fat meal effect | Delays Tmax by ~60 min | Minimal effect | Avoid with liquids other than water | | Renal clearance | Minor | Minor | Minor |

Sources: FDA sildenafil label, FDA vardenafil label.

Men with Diabetes

Diabetes-related ED is notoriously harder to treat than psychogenic or vascular ED in otherwise healthy men. Autonomic neuropathy and endothelial dysfunction blunt the nitric oxide pathway that PDE5 inhibitors rely on.

Sildenafil in Diabetic ED

Goldstein et al. (NEJM 1998, N=532 in the diabetes subgroup analysis) showed sildenafil 25 to 100 mg improved IIEF scores significantly versus placebo, with 56% of men reporting improved erections compared with 10% on placebo (PMID 9580649). That gap is large, but a 44% non-response rate is clinically meaningful and higher than in non-diabetic cohorts.

Vardenafil in Diabetic ED

A dedicated randomized controlled trial by Goldstein et al. (Diabetes Care 2003) tested vardenafil 10 mg and 20 mg in 452 men with type 2 diabetes and ED. Successful intercourse rates were 57% (10 mg) and 72% (20 mg) versus 28% for placebo (PMID 12832311). The 20 mg dose showed an absolute improvement of 44 percentage points over placebo in this difficult-to-treat population.

Head-to-Head Takeaway for Diabetes

No large RCT has directly randomized diabetic men to sildenafil versus vardenafil head-to-head. Indirect comparisons from pooled analyses suggest vardenafil 20 mg may offer a slightly higher success rate in type 2 diabetic men than sildenafil 100 mg, though the confidence intervals overlap. Clinicians at the American Diabetes Association recommend attempting the maximum tolerated PDE5 inhibitor dose before escalating to intracavernosal therapy (ADA Standards of Care 2024).

Men with Cardiovascular Disease

Cardiovascular disease (CVD) is the most common underlying cause of organic ED. The same endothelial dysfunction that clogs coronary arteries impairs penile blood flow. PDE5 inhibitors cause modest systemic vasodilation, which raises safety questions in men already on antihypertensives or nitrates.

Nitrate Contraindication: Both Drugs

Both sildenafil and vardenafil are absolutely contraindicated with organic nitrates. This is a class-wide restriction, not drug-specific. The FDA label for both agents carries a boxed warning about potentially life-threatening hypotension when combined with nitrates (FDA vardenafil label).

Blood Pressure Effects

Sildenafil 100 mg produces a mean maximum decrease of 8.4/5.5 mmHg in healthy volunteers. Vardenafil 20 mg produces a comparable mean decrease of approximately 7/8 mmHg. In men on stable antihypertensive therapy, both drugs add an incremental blood-pressure drop that is usually well tolerated but warrants monitoring.

QTc Prolongation: A Vardenafil-Specific Concern

Vardenafil prolongs the QTc interval by a mean of 8 ms at the 10 mg dose and up to 10 ms at 80 mg (supratherapeutic). The FDA label advises caution in men with congenital QT prolongation or those taking class IA or III antiarrhythmics (FDA vardenafil label). Sildenafil does not carry a QTc warning at therapeutic doses. For men with a documented prolonged QT interval, sildenafil is the safer first choice.

Princeton Consensus Panel Guidance

The Princeton III Consensus recommends stratifying men with CVD into low-, intermediate-, and high-risk groups before prescribing any PDE5 inhibitor. Low-risk men (e.g., controlled hypertension, <3 cardiac risk factors) may start either drug without further cardiovascular evaluation. Intermediate-risk men warrant stress testing first. The panel states: "Sexual activity poses a low cardiovascular risk for men in the low-risk category, and PDE5 inhibitors are appropriate first-line therapy in this group" (Nehra et al., J Sex Med 2012, PMID 22974560).

Post-Prostatectomy ED

Radical prostatectomy damages the cavernous nerves even when nerve-sparing technique is used, leaving men with neurogenic ED that is among the most resistant to oral therapy.

Sildenafil Post-Prostatectomy

Zippe et al. (Urology 1998) found sildenafil restored erections sufficient for intercourse in 72% of men who had bilateral nerve-sparing radical prostatectomy, versus only 15% after non-nerve-sparing surgery (PMID 9886611). Nerve preservation status is the single strongest predictor of PDE5 inhibitor response after prostatectomy.

Vardenafil Post-Prostatectomy

Porst et al. (2003, N=440) randomized men with ED to vardenafil 10 mg, 20 mg, or placebo in a broad population including post-prostatectomy patients. The 20 mg dose achieved statistically significant improvements in IIEF erectile function domain scores versus placebo (P<0.001), and the drug was well tolerated (PMID 12834456). A dedicated post-prostatectomy vardenafil trial by Brock et al. (Urology 2003) showed vardenafil 10 mg and 20 mg significantly improved SEP2 and SEP3 scores in men with bilateral nerve-sparing surgery, with 65% of men achieving successful intercourse on the 20 mg dose versus 13% on placebo (PMID 14624908).

Penile Rehabilitation Programs

Both drugs have been studied for "penile rehabilitation," the practice of regular low-dose PDE5 inhibitor use after prostatectomy to preserve erectile tissue oxygenation. A Cochrane review (Miles et al. 2007) found insufficient evidence to recommend one agent over the other for rehabilitation specifically (Cochrane Library). Many urologists use sildenafil 25 to 50 mg nightly for rehabilitation given its longer post-market experience, while vardenafil is used as an on-demand alternative.

Older Adults (Age 65 and Above)

Aging reduces hepatic blood flow and CYP3A4 activity, slowing drug clearance for both agents. The FDA recommends a starting dose of 5 mg vardenafil (instead of 10 mg) in men 65 and older because plasma concentrations are on average 52% higher in this age group (FDA vardenafil label). Sildenafil's recommended starting dose in men over 65 is 25 mg.

Efficacy in Older Men

A pooled analysis of vardenafil phase III trials showed that men 65 years and older achieved significant improvements in IIEF scores with vardenafil 5 to 20 mg, with response rates similar to younger men when appropriate doses were used. Sildenafil similarly retains efficacy in older men, though the 25 mg starting dose may require titration to 50 or 100 mg for full benefit.

Falls and Orthostatic Hypotension Risk

Both PDE5 inhibitors can cause orthostatic hypotension, a concern in older adults who may already be on alpha-blockers for benign prostatic hyperplasia (BPH). The FDA label for vardenafil specifies a minimum 6-hour separation between vardenafil and tamsulosin to prevent symptomatic hypotension. The same precaution applies to sildenafil. For men on alpha-blockers, starting at the lowest possible PDE5 inhibitor dose reduces fall risk.

Renal Impairment

Sildenafil in Renal Impairment

Men with creatinine clearance <30 mL/min show a 100% increase in sildenafil AUC compared to men with normal renal function. The FDA recommends a 25 mg starting dose in severe renal impairment (FDA sildenafil label). Hemodialysis does not appreciably remove sildenafil.

Vardenafil in Renal Impairment

Vardenafil pharmacokinetics are not significantly altered by renal impairment, including end-stage renal disease. No dose adjustment is required for any degree of renal impairment, giving vardenafil a practical advantage in men with chronic kidney disease or on dialysis (FDA vardenafil label).

Hepatic Impairment

Sildenafil in Liver Disease

Moderate hepatic impairment (Child-Pugh class B) increases sildenafil AUC by 84%. Start at 25 mg and titrate with caution. Sildenafil is not recommended in severe hepatic impairment (Child-Pugh class C) due to absent safety data (FDA sildenafil label).

Vardenafil in Liver Disease

Moderate hepatic impairment increases vardenafil AUC by 160%. Start at 5 mg and do not exceed 10 mg in Child-Pugh class B. Vardenafil is also not recommended in severe hepatic impairment. Both drugs share the same contraindication in severe liver disease, but vardenafil requires a lower ceiling dose in moderate impairment.

Side-Effect Profile Comparison

| Side Effect | Sildenafil | Vardenafil | Notes | |---|---|---|---| | Headache | ~16% | ~15% | Similar rates | | Flushing | ~10% | ~11% | Similar rates | | Dyspepsia | ~7% | ~4% | Sildenafil slightly higher | | Nasal congestion | ~4% | ~9% | Vardenafil higher | | Visual disturbances | ~3% | <1% | Sildenafil higher (PDE6) | | QTc prolongation | No | Yes (mean +8 ms) | Vardenafil-specific | | Back pain/myalgia | ~2% | ~2% | Similar |

Data synthesized from FDA prescribing information and Porst et al. 2003 (PMID 12834456).

Drug Interactions Across Both Agents

CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) raise plasma levels of both drugs substantially. Ritonavir increases sildenafil AUC by 11-fold; the FDA caps sildenafil at 25 mg every 48 hours in men on ritonavir (FDA sildenafil label). Ketoconazole 200 mg increases vardenafil AUC 10-fold; the vardenafil label caps the dose at 5 mg per 24 hours with potent CYP3A4 inhibitors. Men on HIV protease inhibitors or antifungals should discuss dose adjustments with their prescriber before starting either drug.

Switching from Viagra to Vardenafil: Clinical Guidance

Switching is appropriate when sildenafil produces inadequate erections, intolerable side effects (particularly visual disturbances or severe flushing), or when a man's comorbidities favor vardenafil (e.g., chronic kidney disease, preference for a lower-potency starting point).

When to Consider the Switch

• Visual disturbances on sildenafil (blue tint, photosensitivity): vardenafil's better PDE6 selectivity may resolve this.
• Chronic kidney disease: vardenafil requires no renal dose adjustment.
• Inconsistent response with high-fat meals: vardenafil is less affected by food.
• Dyspepsia on sildenafil: rates are lower with vardenafil.

When to Stay on Sildenafil

• Documented QTc prolongation or antiarrhythmic use (class IA or III): sildenafil is safer.
• Need for the widest available generic options at lowest cost: sildenafil generics are more widely available and less expensive.
• Preference for the longest clinical evidence base: sildenafil has been on market since 1998 versus vardenafil's 2003 approval.

Practical Switching Protocol

Start vardenafil at the standard 10 mg dose (or 5 mg if age 65 or older, moderate hepatic impairment, or on a moderate CYP3A4 inhibitor). Allow at least 6 to 8 attempts at a given dose before concluding inadequate response, per AUA Erectile Dysfunction Guidelines 2018 (AUA Guidelines). Titrate to 20 mg if 10 mg is tolerated but insufficient. Do not combine with the previous sildenafil prescription during the transition; a minimum washout of 24 hours is adequate given both drugs' half-lives.

Staxyn (Vardenafil ODT): A Distinct Formulation

Staxyn is vardenafil 10 mg as an orally disintegrating tablet (ODT). It dissolves on the tongue without water. Bioavailability is slightly higher than the conventional tablet at the same dose, so Staxyn 10 mg should not be substituted milligram-for-milligram with Levitra 10 mg in men at the low end of blood pressure tolerability. Staxyn has no generic equivalent as of 2025. Men who prefer discretion (no water needed, dissolves in seconds) or who have difficulty swallowing tablets represent the primary use case. The FDA approved Staxyn in 2010 (FDA approval history).

Head-to-Head Summary Table

| Clinical Scenario | Preferred Agent | Reasoning | |---|---|---| | Diabetes (type 2, severe ED) | Vardenafil 20 mg | Higher success rates in dedicated RCTs | | Post-prostatectomy, bilateral nerve-sparing | Either; sildenafil 50 to 100 mg or vardenafil 20 mg | Similar evidence base; titrate to response | | QTc prolongation or antiarrhythmic use | Sildenafil | No QTc effect | | Chronic kidney disease | Vardenafil | No renal dose adjustment needed | | Moderate hepatic impairment | Sildenafil (with lower starting dose) | Smaller AUC increase than vardenafil | | Visual disturbances on current PDE5 inhibitor | Vardenafil | Higher PDE6 selectivity | | Age 65 or older | Either at reduced starting dose | Both require lower starting doses | | HIV protease inhibitor use | Sildenafil 25 mg q48h | Both restricted; sildenafil has more data | | Preference for ODT formulation | Staxyn (vardenafil 10 mg ODT) | Only ODT PDE5 inhibitor available | | Lowest cost | Sildenafil generic | Wider generic availability |